Fulcrum Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 26.14 million compared to USD 23.48 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.58 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.105 USD | -0.92% | +4.33% | +19.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.63% | 508M | |
+45.19% | 56.65B | |
-7.25% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.01% | 26.75B | |
-21.48% | 19.03B | |
+1.27% | 12.28B | |
+23.93% | 12.26B | |
+27.41% | 12.04B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022